Chronic Kidney Disease / Obesity / Overweight · Phase 2 Trial

A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

ClinicalTrials.gov · September 11, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a Phase 2 registry record for a completed but unpublished trial of tirzepatide versus placebo in 134 participants with obesity and chronic kidney disease, with or without type 2 diabetes. The primary outcome is change in renal sinus fat content by MRI at 52 weeks. No results are posted in this registry record, so the efficacy, safety, or clinical significance of the intervention cannot yet be assessed.

What was studied

Phase 2, Interventional, Randomized, Parallel, Double masking, Treatment purpose. Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D; age from 18 Years. Intervention: Tirzepatide. Compared with: Placebo — Placebo Comparator. n = 134. 27 sites across 6 countries.

Key findings

Safety

No results reported in this registry record; outcomes, effect sizes, and safety data are not available.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

Phase 2 registry record with completed enrollment but no results posted; insufficient to assess efficacy or safety, only study design and conduct are known.

Study design

As stated by the source record.

MethodsPrimary outcome measure: Percent Change from Baseline in Renal Sinus Fat Content (MRI) (assessed at Baseline, Week 52)

DesignPhase 2, Interventional, Randomized, Parallel, Double masking, Treatment purpose

PopulationOverweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D; age from 18 Years

Sample size134

InterventionTirzepatide

ComparatorPlacebo — Placebo Comparator

Setting27 sites across 6 countries

Reported figures

Quoted from the source exactly as published.

Planned enrollment134

PhasePhase 2

Primary outcome measurePercent Change from Baseline in Renal Sinus Fat Content (MRI), Baseline, Week 52

Study duration56 weeks

Caveats

No results reported in this registry record; outcomes, effect sizes, and safety data are not available.
Primary endpoint is a surrogate marker (renal sinus fat on MRI), not a clinical hard endpoint such as kidney function decline or cardiovascular event.
Randomization method, blinding strategy, and allocation concealment are not described in the registry record.
Generalizability to broader populations and settings unknown without published results and detailed methodology.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

moderate

Phase 2, randomized controlled trial with placebo comparator; design appropriate for exploratory efficacy.

Directness

moderate

Primary endpoint is renal sinus fat by MRI; surrogate marker, not a clinical hard endpoint.

Consistency

insufficient

Single trial; no results posted for comparison with other evidence.

Risk of bias

insufficient

Registry record does not report methods of randomization, blinding, or allocation concealment.

Sample adequacy

limited

N=134 total for Phase 2 exploratory study; modest size for definitive inference.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT05536804). This is a study registration, not published results. Lead sponsor: Eli Lilly and Company. Recruitment status: COMPLETED. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 134 participants (ACTUAL). Conditions: Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D. Interventions: DRUG: Tirzepatide; DRUG: Placebo. Primary outcome measures: Percent Change from Baseline in Renal Sinus Fat Content (MRI) , Baseline, Week 52. Brief summary: We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or without type 2 diabetes (T2D). The study will last about 56 weeks and include up to 12 visits.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Eli Lilly and CompanyChronic Kidney DiseaseObesityOverweightTirzepatideNCT05536804